Future research should focus on the following directions: (1) developing multi-omics technologies to analyze the dynamic evolution of resistance; (2) exploring combination therapeutic strategies targeting both tumor cells and the microenvironment; (3) achieving precise classification based on biomarkers such as TMB and the spatial distribution of PD-L1; (4) developing efficient and low-toxicity immunotherapy combination models. Here, CD274 is linked to neoplasm.